Functional RNAi and CRISPR Screening and Drug Target & Biomarker Discovery
Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high-throughput functional genetic screening portfolio includes:
- shRNA and CRISPR screening services
- custom and off-the-shelf pooled libraries
- knockout and knockdown cell lines
that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
With DriverMap™ Targeted Gene Expression Profiling Service, Cellecta offers a quantitative, multiplexed approach that allows simultaneous profiling of all human protein-coding genes in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
Cell Symposia – CRISPR: From Biology to Technology and Novel Therapeutics, Sitges, Spain, October 22-24, 2017
FEBS3+ Joint Meeting of the French-Portuguese-Spanish Biochemical and Molecular Biology Societies, Fira de Barcelona, Barcelona, Spain, October 25, 2017
Cellecta Workshop: Wednesday, October 25, 11:00 – 12:00 pm
2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Philadelphia Convention Center, Philadelphia, PA, October 26-30, 2017
Booth # 605.
With DriverMap, Cellecta offers a novel, comprehensive end-to-end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA, detecting cellular composition, and profiling immunotherapy targets.
Cellecta, partnered with RPCI, FHCRC, and TSRI has created one of the most effective and published pooled shRNA library platforms available. We now also offer pooled premade and custom CRISPR libraries.
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.